Comparison of TERRA expression in human brain tumors
Keywords:
Expression, TERRA, Meningioma, AstrocytomaAbstract
Telomerase activation has been found in a variety of human cancers, including brain tumors to prevent the telomere from progressive shortening, but telomeres are transcribed into a non-coding RNA called telomeric repeat-containing RNA or TERRA which acts as a natural inhibitor of telomerase activity. Considering meningioma and astrocytoma are the most common tumors of the CNS, the aim of this study was to evaluate TERRA expression level in meningioma, astrocytoma tumors and nontumor (NT) controls. Furthermore, expression levels of TERRA were compared between different grades of meningioma and astrocytoma. Additionally, we analyzed the correlation of TERRA expression and improvement outcome. The total RNA of 51 brain tumor samples and 4 samples as nontumor (NT) controls was extracted and SYBR Green real-time reverse transcription–polymerase chain reaction assays for quantitation of total TERRA levels were developed. Tumor samples from 25 patients with meningiomas and 26 patients with astrocytoma were assessed. We demonstrated the correlation between total TERRA levels of expression with different grades of brain tumors and improvement outcome. According to our study, TERRA may be a prognostic marker in meningioma and astrocytoma tumors.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.